Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.710
-0.150 (-8.06%)
At close: Dec 5, 2025, 4:00 PM EST
1.661
-0.049 (-2.89%)
After-hours: Dec 5, 2025, 7:31 PM EST
Jasper Therapeutics Stock Forecast
JSPR's stock price has decreased by -92.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Jasper Therapeutics stock have an average target of 25.6, with a low estimate of 4.00 and a high estimate of 65. The average target predicts an increase of 1,397.08% from the current stock price of 1.71.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Jasper Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +133.92% | Nov 11, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $20 → $14 | Buy | Maintains | $20 → $14 | +718.71% | Sep 22, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $12 → $6 | Buy | Maintains | $12 → $6 | +250.88% | Sep 22, 2025 |
| BTIG | BTIG | Strong Buy Maintains $20 → $7 | Strong Buy | Maintains | $20 → $7 | +309.36% | Sep 22, 2025 |
| UBS | UBS | Strong Buy Maintains $29 → $25 | Strong Buy | Maintains | $29 → $25 | +1,361.99% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.62
from -4.89
EPS Next Year
-2.46
from -4.62
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.05 | -1.34 | ||||
| Avg | -4.62 | -2.46 | ||||
| Low | -5.13 | -3.23 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.